stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Total debt
Kymera Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $1.5M, down 34.3% from $2.2M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $602.0K. Over the past ten years it has ranged from $604.0K (fiscal 2020) to $2.2M (fiscal 2024); the current reading is higher than 88% of that period. Kymera Therapeutics, Inc. ranks 416th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.5M | (34.32%) |
| FY2024 | $2.2M | 71.10% |
| FY2023 | $1.3M | 4.41% |
| FY2022 | $1.2M | 9.30% |
| FY2021 | $1.1M | 88.74% |
| FY2020 | $604.0K | (48.15%) |
| FY2019 | $1.2M | 67.63% |
| FY2018 | $695.0K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $602.0K | (28.33%) |
| Jun 2026 | $840.0K | (27.02%) |
| Mar 2026 | $1.2M | (21.27%) |
| Dec 2025 | $1.5M | (18.96%) |
| 22 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $4.2B |
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| TECH Bio-Techne Corp compare | $200.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| PCVX Vaxcyte, Inc. compare | $14.0M |
| KYMR Kymera Therapeutics, Inc. | $602.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement